Alimera sciences reports inducement grants under nasdaq listing rule 5635(c)(4)

Atlanta, june 04, 2024 (globe newswire) -- alimera sciences, inc. (nasdaq: alim) (“alimera” or the “company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to nasdaq listing rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the compensation committee of the board of directors of the company (the “compensation committee”) approved, on may 22, 2024 (the “grant date”), inducement awards consisting of stock options under the alimera sciences, inc. 2024 equity inducement plan to persons who were not previously employees or who rejoined the company following a bona fide period of non-employment, as an inducement material to each such new or re-hired employee's employment (collectively, the “inducement awards”).
ALIM Ratings Summary
ALIM Quant Ranking